MyMyelomaTeam

Peripheral neuropathy is indeed very common with myeloma — around 75% of people with myeloma develop it during treatment. So unfortunately, it affects the majority of patients. There are two main reasons it develops:

- The myeloma itself can damage nerves directly
- Chemotherapy-induced peripheral neuropathy (CIPN) is the Show Full Answer

Peripheral neuropathy is indeed very common with myeloma — around 75% of people with myeloma develop it during treatment. So unfortunately, it affects the majority of patients. There are two main reasons it develops:

- The myeloma itself can damage nerves directly
- Chemotherapy-induced peripheral neuropathy (CIPN) is the primary cause, as many induction therapy drugs are known to affect the nerves

The good news is that neuropathy sometimes improves once treatment is completed or if the dose is reduced. One MyMyelomaTeam member shared that after experiencing severe numbness and bone pain during treatment, they walked without assistance for 10 years afterward.

That said, for some people it can persist long-term, so it's important to flag any symptoms to your doctor early. They may be able to adjust your dosage or explore management options.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Managing Peripheral Neuropathy in Myeloma